11,836 results match your criteria Cutaneous T-Cell Lymphoma


Influence of the phenotype on mycosis fungoides prognosis, a retrospective cohort study of 160 patients.

Int J Dermatol 2019 Feb 14. Epub 2019 Feb 14.

Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada.

Background: Mycosis fungoides (MF) typically has a CD4 CD8 T-cell phenotype. Rare cases of CD4 CD8 , CD4 CD8 , or CD4 CD8 immunophenotypes have been described. Little is known about the impact of MF immunophenotypes on disease behavior. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ijd.14391
Publisher Site
http://dx.doi.org/10.1111/ijd.14391DOI Listing
February 2019
3 Reads

Prognostic Significance of Serum Copper in Patients With Cutaneous T-cell Lymphoma.

Clin Lymphoma Myeloma Leuk 2019 Jan 2. Epub 2019 Jan 2.

University of Arizona, Tucson, AZ.

Background: Serum copper has been reported to be increased in various cancers, including lymphoma. The purpose of the present study was to investigate the clinical and prognostic importance of serum copper levels in patients with cutaneous T-cell lymphoma (CTCL).

Patients And Methods: Serum copper was measured in 60 men and 38 women with mycosis fungoides (MF) and 14 men and 3 women with erythrodermic CTCL (6 with Sézary syndrome) consecutively evaluated from July 1980 to June 1985. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183144
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.12.020DOI Listing
January 2019
4 Reads

Paraneoplastic scleroderma in the setting of CD30 large cell transformation of mycosis fungoides.

JAAD Case Rep 2019 Feb 31;5(2):201-204. Epub 2019 Jan 31.

Columbia University Medical Center, Department of Dermatology, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.11.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357550PMC
February 2019
1 Read

Oral mycosis fungoides with CD30 large cell transformation successfully treated with brentuximab vedotin.

JAAD Case Rep 2019 Feb 30;5(2):180-183. Epub 2019 Jan 30.

Georgetown University School of Medicine, Department of Dermatology, Washington, DC.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23525126183034
Publisher Site
http://dx.doi.org/10.1016/j.jdcr.2018.11.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357896PMC
February 2019
2 Reads

Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.

Proc Natl Acad Sci U S A 2019 Feb 4. Epub 2019 Feb 4.

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231;

Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-toxin-based fusion protein that depletes CD25-positive cells including regulatory T cells and has been approved for the treatment of persistent or recurrent cutaneous T cell lymphoma. However, the clinical use of denileukin diftitox was limited by vascular leak toxicity and production issues related to drug aggregation and purity. We found that a single amino acid substitution (V6A) in a motif associated with vascular leak induction yields a fully active, second-generation biologic, s-DAB-IL-2(V6A), which elicits 50-fold less human umbilical vein endothelial cell monolayer permeation and is 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1815087116DOI Listing
February 2019
1 Read
9.809 Impact Factor

Single-cell profiling of cutaneous T-cell lymphoma reveals underlying heterogeneity associated with disease progression.

Clin Cancer Res 2019 Feb 4. Epub 2019 Feb 4.

Dermatology, University of Iowa

Purpose: Cutaneous T cell lymphomas (CTCL), encompassing a spectrum of T-cell lymphoproliferative disorders involving the skin, have collectively increased in incidence over the last 40 years. Sézary syndrome (SS) is an aggressive form of CTCL characterized by significant presence of malignant cells in both the blood and skin. The guarded prognosis for SS reflects a lack of reliably effective therapy, due in part to an incomplete understanding of disease pathogenesis. Read More

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-3309DOI Listing
February 2019
11 Reads

Follicular mucinosis in patients with hematologic malignancies other than mycosis fungoides: A clinicopathologic study.

J Am Acad Dermatol 2019 Feb 1. Epub 2019 Feb 1.

Department of Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.

Background: Follicular mucinosis (FM), defined by mucin accumulation within follicular epithelium, may occur in mycosis fungoides (MF). FM without MF is occasionally reported in systemic hematologic malignancies, and may be diagnostically challenging.

Objective: To describe clinicopathological characteristics of FM in patients with hematologic malignancies other than MF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.01.062DOI Listing
February 2019
1 Read

Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).

Aesthet Surg J 2019 Jan;39(Supplement_1):S14-S20

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a newly included provisional entity in the 2016 revision of the World Health Organization classification, is a distinct form of CD30-positive T-cell non-Hodgkin lymphoma that arises in association with a breast implant after reconstructive or cosmetic surgery. In addition to its characteristic clinical presentation, recent studies using next-generation sequencing have revealed that BIA-ALCL has a unique pattern of genetic alterations. BIA-ALCL is consistently negative for ALCL-related gene rearrangements involving ALK, DUSP22, and TP63. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/asj/sjy311DOI Listing
January 2019
2 Reads

Does continuous subcutaneous infusion of lignocaine relieve intractable pruritus associated with advanced cutaneous T-cell lymphoma? A retrospective case series review.

Palliat Med 2019 Feb 4:269216319828189. Epub 2019 Feb 4.

4 Division of Palliative Care, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia.

Background:: Intractable pruritus affects an estimated 83% of patients with advanced cutaneous T-cell lymphoma. Palliative care strategies to improve outcomes for these patients are lacking. Lignocaine antagonises kappa opioid antagonist-induced scratching in mice models and may relieve cutaneous T-cell lymphoma-pruritus. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0269216319828189
Publisher Site
http://dx.doi.org/10.1177/0269216319828189DOI Listing
February 2019
5 Reads

[Primary skin lymphomas: Current therapy].

Authors:
O Dereure

Ann Dermatol Venereol 2019 Jan 29. Epub 2019 Jan 29.

Unité Inserm U1058, département de dermatologie, université Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France. Electronic address:

Therapeutic progress in primary cutaneous lymphomas continues to be largely dominated by the T-cell lymphomas, towards which the great majority of recent therapeutic innovations have been directed. The latter include local treatments consisting either of relatively classical but "revamped" approaches involving different pharmaceutical forms (example: chlormethine gel) or else lower but seemingly equally effective dosages (electron therapy), or of more innovative approaches (example: UVA-1, dynamic phototherapy, imiquimod, resimiquimod). However, significant progress has been made chiefly in terms of systemic treatments with the emergence of "targeted" drugs that directly and specifically target tumour cells (monoclonal antibodies directed against CD30, CCR4 or CD158k) and the further development of "small" molecules such as histone deacetylase inhibitors and new cytostatics. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01519638183135
Publisher Site
http://dx.doi.org/10.1016/j.annder.2018.11.012DOI Listing
January 2019
4 Reads

Mature (non-anaplastic, non-cutaneous) T-/NK-cell lymphomas in children, adolescents and young adults: state of the science.

Br J Haematol 2019 Feb 1. Epub 2019 Feb 1.

Department of Pediatrics, New York Medical College, Valhalla, NY, USA.

Mature (non-anaplastic) T-cell and natural killer (NK)-lymphomas rarely occur in children or adolescents. Due to the low incidence and heterogeneity, information regarding the aetiology, physiopathology and genetics of paediatric mature (non-anaplastic) T/NK-cell lymphoma is lacking. In addition, standard treatments have not yet been established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15767DOI Listing
February 2019
1 Read

Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders.

Front Pediatr 2018 17;6:405. Epub 2019 Jan 17.

Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

Epstein Barr virus positive T/NK lymphoproliferative disorders (EBV-TNKLPD) comprise a spectrum of neoplasms ranging from cutaneous lymphoid proliferations to aggressive lymphomas. The spectrum includes extranodal NK/T-cell lymphoma (ENKTL), aggressive NK-cell leukemia, and a group of EBV-TNKLPDs affecting children which are poorly characterized in terms of their molecular biology. Gene and miRNA expression profiling has elucidated RNA abnormalities which impact on disease biology, classification, and treatment of EBV-TNKLPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2018.00405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344448PMC
January 2019
1 Read

Response to «Cutaneous eruptions associated with hematologic malignancies : the need for a unifying nomenclature».

J Eur Acad Dermatol Venereol 2019 Jan 31. Epub 2019 Jan 31.

Service d'Oncodermatologie, Hôpital Robert Debré, Reims, France.

We read with interest Maglie et al's comments to "T-cell papulosis associated with B-cell malignancy (TCP-BCM): a distinctive clinicopathologic entity"(1,2). These authors conducted a study focusing on "eosinophilic dermatosis of hematologic malignancies" (EDHM) and TCP-BCM, and suggest that although this eruption is mostly associated with BCMs, it may also occur with other hematological malignancies (HM) such as acute myeloid leukemia or T-cell lymphoma, or even different inflammatory conditions. In our study, we excluded non B-cell malignancies because i) they are possibly associated with a wider spectrum of cutaneous manifestations (3,4) ii) in our clinical experience, TCP-BCM was always associated with chronic lymphocytic leukemia (CLL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15451DOI Listing
January 2019
6 Reads

Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis.

JAMA Dermatol 2019 Jan 30. Epub 2019 Jan 30.

Department of Dermatology, Liverpool Hospital, Liverpool, Sydney, Australia.

Importance: Phototherapy is one of the mainstays of treatment for early mycosis fungoides (MF). The most common modalities are psoralen-UV-A (PUVA) and narrowband UV-B (NBUVB).

Objective: To compare the efficacy and adverse effects of PUVA vs NBUVB in early-stage MF. Read More

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2018.5204DOI Listing
January 2019
4 Reads

Hypo-pigmented mycosis fungoides is a rare malignancy in pediatrics.

Dermatol Online J 2018 Nov 15;24(11). Epub 2018 Nov 15.

Hematology Research Center, Shiraz University of Medical Sciences, Shiraz.

Hypopigmented mycosis fungoides (HMF) is an uncommon form of cutaneous T-cell lymphoma. It can be seen in children and is usually mistaken for eczema, vitiligo, or progressive macular hypomelanosis, clinically and histopathologically. We present a boy with HMF confirmed by histopathology. Read More

View Article

Download full-text PDF

Source
November 2018
5 Reads

Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).

Chin Clin Oncol 2019 Jan 9. Epub 2019 Jan 9.

Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA; Sidney Kimmel Cancer Center at Jefferson Health, Philadelphia, PA, USA.

Mycosis fungoides (MF) and Sézary syndrome (SS) are two well-characterized skin limited and leukemic subtypes of cutaneous T-cell lymphoma (CTCL), respectively. Progressive global immune dysfunction and a multitude of specific immunological abnormalities have long been recognized as features of MF and SS. Therefore, a variety of immune-based therapies have been explored and used in the clinic for decades in the attempt to restore the immune imbalance in these malignancies. Read More

View Article

Download full-text PDF

Source
http://cco.amegroups.com/article/view/23332
Publisher Site
http://dx.doi.org/10.21037/cco.2019.01.01DOI Listing
January 2019
15 Reads

The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.

Chin Clin Oncol 2019 Jan 9. Epub 2019 Jan 9.

Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

Primary cutaneous CD30+ T cell lymphoproliferative disorders (pcCD30+ T cell LPDs) are a spectrum of pre-malignant to frankly neoplastic lymphoproliferations that comprise lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions. Although the atypical T cells that are the hallmark of these disorders share the expression of CD30, as the identifying marker, the clinical presentation, histological features and clinical course are vastly different. Furthermore, histopathologic features of pcCD30+ T cell LPDs may overlap with other cutaneous and systemic lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2018.12.03DOI Listing
January 2019
1 Read

MicroRNAs in Cutaneous T-Cell Lymphoma: The Future of Therapy.

J Invest Dermatol 2019 Jan 24. Epub 2019 Jan 24.

Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA; Division of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio USA; Department of Medical Oncology, Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Electronic address:

MicroRNAs (miRs) are small, noncoding RNAs with numerous cellular functions. With advancing knowledge of the many functions of miRs in cancer pathogenesis, there is emerging interest in miRs as therapeutic targets in cancers. One disease that poses an intriguing model for miR therapy is cutaneous T-cell lymphoma, a rare disease featuring malignant CD4 T cells that proliferate in the skin. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022202X183281
Publisher Site
http://dx.doi.org/10.1016/j.jid.2018.10.035DOI Listing
January 2019
3 Reads

Subcutaneous panniculitis-like T-cell lymphoma responsive to combination therapy with methotrexate and corticosteroids.

Dermatol Online J 2018 Sep 15;24(9). Epub 2018 Sep 15.

Department of Dermatology, Oregon Health & Science University, Portland, Oregon.

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare condition that falls underneath the umbrella of primary cutaneous T-cell lymphomas (CTCLs). SPTCL can be very difficult to diagnose as it may mimic other subtypes of CTCL, such as γ/δ T-cell lymphoma (TCL), or other forms of panniculitis. Confirmation of diagnosis often requires immunohistochemical analysis and is essential for proper prognosis and therapeutic management. Read More

View Article

Download full-text PDF

Source
September 2018
5 Reads

The development of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder at the site of a melanoma excision scar.

Dermatol Online J 2018 Sep 15;24(9). Epub 2018 Sep 15.

University of Texas Health Science Center, McGovern Medical School, Houston, Texas Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder (PCSM-LPD) is a rare and low-grade form of cutaneous T-cell lymphoma (CTCL), representing 2% of all primary cutaneous lymphomas. Because of its rarity, the etiology or exact clinicopathology of PCSM-LPD remains unclear. We present the first case of PCSM-LPD, to our knowledge, arising at a past melanoma excision site. Read More

View Article

Download full-text PDF

Source
September 2018
1 Read

Lymphomatoid papulosis.

Dermatol Online J 2018 Dec 15;24(12). Epub 2018 Dec 15.

The Ronald O. Perelman Department of Dermatology, New York University Langone Medical Center, New York, New York.

Lymphomatoid papulosis is often regarded as a low-grade variant of cutaneous T cell lymphoma (CTCL). Given the excellent long-term prognosis, recent consensus guidelines indicate that patients can be monitored off therapy. We report a case of a 67-year-old man who presented with lymphomatoid papulosis, with necrotic papules that have been intermittently present for over forty years. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

Folliculotropic mycosis fungoides.

Dermatol Online J 2018 Dec 15;24(12). Epub 2018 Dec 15.

The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York.

Folliculotropic mycosis fungoides (MF) is a distinct subset of cutaneous T cell lymphoma (CTCL). The disease is typically marked by an aggressive course and is often recalcitrant to skin-direct therapy. We report a case of an 83-year-old woman with folliculotropic MF characterized by erythematous, scaly plaques on the forehead along with poliosis and alopecia of the right medial eyebrow. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

Decolonization of in Healthcare: A Dermatology Perspective.

J Healthc Eng 2018 24;2018:2382050. Epub 2018 Dec 24.

Department of Dermatology, Tulane University, New Orleans, LA, USA.

The bacterium is responsible for significant morbidity, mortality, and financial burden in healthcare. It easily colonizes susceptible patients and can cause recurrent infections, especially in populations at risk. In addition to treating sequelae of infections, there is a growing body of literature aimed at decolonizing susceptible patients in order to prevent infection and also to prevent spread. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/jhe/2018/2382050/
Publisher Site
http://dx.doi.org/10.1155/2018/2382050DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323510PMC
December 2018
7 Reads

Zinc-dependent deacetylase (HDAC) inhibitors with different ZBG groups.

Curr Top Med Chem 2019 Jan 22. Epub 2019 Jan 22.

State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang 550004. China.

The state of histone acetylation plays a very crucial role in carcinogenesis and its development by chromatin remodeling and thus altering transcription of oncogenes and tumor suppressor genes. Such epigenetic regulation was controlled by zinc-dependent histone deacetylases (HDACs), one of major regulators. Due to the therapeutic potential of HDACs as one of promising drug targets in cancer, HDAC inhibitors have been intensively investigated over last few decades. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/169245/article
Publisher Site
http://dx.doi.org/10.2174/1568026619666190122144949DOI Listing
January 2019
3 Reads
3.402 Impact Factor

Primary cutaneous CD8+ and CD30+ T-cell lymphoproliferative disorders: case reports and clinical implications.

Eur J Dermatol 2019 Jan 21. Epub 2019 Jan 21.

Department of Pathology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels.

Background: CD8+ CD30+ primary cutaneous T-cell lymphomas (PCTCL) are rare entities with overlapping pathological features and variable outcome.

Objectives: We sought to highlight the importance of correlation between pathological findings and clinical presentation for correct classification of the disease.

Material & Methods: Two cases of CD8+ CD30+ PCTCL were investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3493DOI Listing
January 2019
13 Reads

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.

J Clin Oncol 2019 Jan 18:JCO1800501. Epub 2019 Jan 18.

23 The University of Tokyo, Tokyo, Japan.

Purpose: Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diverse clinical features, multidrug resistance of malignant cells, frequent large tumor burden, hypercalcemia, and/or frequent opportunistic infection. In 2009, we published a consensus report to define prognostic factors, clinical subclassifications, treatment strategies, and response criteria. Read More

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00501
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00501DOI Listing
January 2019
7 Reads

Dermoscopy in lymphoproliferative disorders - experience from a cutaneous lymphoma clinic in a tertiary cancer center.

J Am Acad Dermatol 2019 Jan 14. Epub 2019 Jan 14.

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.12.064DOI Listing
January 2019
1 Read

Mycosis fungoides presenting as vulvar plaques.

J Eur Acad Dermatol Venereol 2019 Jan 17. Epub 2019 Jan 17.

Department of Dermatology, Saint-Louis Hospital, APHP, Paris Diderot University, INSERM U976, Paris, France.

Mycosis fungoides (MF), the most frequent type of cutaneous T-cell lymphoma, is characterized in the early stage by patches and plaques that predominate in sun-protected areas. MF is rarely associated with vulvar involvement. We report two cases of MF with predominant vulvar lesions. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jdv.15429
Publisher Site
http://dx.doi.org/10.1111/jdv.15429DOI Listing
January 2019
5 Reads

The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Blood 2019 Jan 11. Epub 2019 Jan 11.

Hematopathology section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, United States.

Primary cutaneous lymphomas are a heterogeneous group of T-cell lymphomas and B-cell lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. In the last decade the 2005 WHO-EORTC consensus classification has served as a golden standard for the diagnosis and classification of these conditions. In September 2018 an updated version of the WHO-EORTC was published in the 4th edition of the WHO classification for Skin Tumours Blue Book. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-881268DOI Listing
January 2019
23 Reads

Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?

Authors:
Stephen M Ansell

Leuk Lymphoma 2019 Jan 11:1-2. Epub 2019 Jan 11.

a Division of Hematology , Mayo Clinic , Rochester , Minnesota 55905 , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1543887DOI Listing
January 2019
10 Reads

CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.

Haematologica 2019 Feb 10;104(2):226-235. Epub 2019 Jan 10.

Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Madrid.

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.197152DOI Listing
February 2019
3 Reads

[Single-center retrospective analysis of extracorporal photopheresis in clinical practice : Peripheral venous compared to central venous access].

Hautarzt 2019 Jan 9. Epub 2019 Jan 9.

Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Mannheim, Ruprecht-Karls-Universität Heidelberg, Mannheim, Deutschland.

Background: Extracorporal photopheresis (ECP) was shown to be effective without severe side effects in the treatment of cutaneous T cell lymphoma (CTCL) and graft versus host disease (GvHD). However, only few studies investigated the practical aspects of ECP.

Methods: Treatment protocols of 2038 ECP procedures in 52 patients (CTCL, n = 29; GvHD, n = 15; other, n = 8) were evaluated. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00105-018-4327-y
Publisher Site
http://dx.doi.org/10.1007/s00105-018-4327-yDOI Listing
January 2019
5 Reads

Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma.

JCI Insight 2019 Jan 10;4(1). Epub 2019 Jan 10.

Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Psoralen plus UVA (PUVA) is an effective therapy for mycosis fungoides (MF), the skin-limited variant of cutaneous T cell lymphoma (CTCL). In low-burden patients, PUVA reduced or eradicated malignant T cells and induced clonal expansion of CD8+ T cells associated with malignant T cell depletion. High-burden patients appeared to clinically improve but large numbers of malignant T cells persisted in skin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.124233DOI Listing
January 2019
6 Reads

HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.

Cancer Res 2019 Jan 8. Epub 2019 Jan 8.

The Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.

Chimeric antigen receptors (CAR) can transmit signals akin to those from activated T-cell receptors when bound to a cell surface target. CAR-expressing T cells against CD19 can cause curative effects in leukemia and lymphoma and is approved for clinical use. However, no CAR-T therapy is currently approved for use in solid tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-3158DOI Listing
January 2019
16 Reads

Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.

J Med Internet Res 2019 Jan 7;21(1):e11302. Epub 2019 Jan 7.

PatientsLikeMe, Inc, Cambridge, MA, United States.

Background: Although the quality of life (QoL) plays an important role in treatment decision making and clinical management of mycosis fungoides (MF) or Sézary syndrome (SS) subtypes of cutaneous T-cell lymphomas (MF/SS-CTCLs), an MF- or SS-specific measure of QoL does not exist.

Objective: The objective of this research was to develop and validate the first QoL instrument for MF/SS-CTCL using a patient-centered approach.

Methods: A conceptual framework for the MF/SS-CTCL QoL was developed through a literature review and interviews with key opinion leaders. Read More

View Article

Download full-text PDF

Source
https://www.jmir.org/2019/1/e11302/
Publisher Site
http://dx.doi.org/10.2196/11302DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329422PMC
January 2019
14 Reads

SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?

Clin Immunol 2018 Oct 25. Epub 2018 Oct 25.

Department of Molecular and Cellular Pathobiology, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology National Academy of Sciences of Ukraine, Kyiv, Ukraine.

SLAMF1/CD150 receptor is a founder of signaling lymphocyte activation molecule (SLAM) family of cell-surface receptors. It is widely expressed on cells within hematopoietic system. In hematologic malignancies CD150 cell surface expression is restricted to cutaneous T-cell lymphomas, few types of B-cell non-Hodgkin's lymphoma, near half of cases of chronic lymphocytic leukemia, Hodgkin's lymphoma, and multiple myeloma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216616183043
Publisher Site
http://dx.doi.org/10.1016/j.clim.2018.10.015DOI Listing
October 2018
6 Reads

Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma.

Br J Haematol 2019 Jan 6. Epub 2019 Jan 6.

Department of Haematology, Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15744DOI Listing
January 2019
2 Reads

The clinical value of imaging in primary cutaneous lymphomas: Role of high resolution ultrasound and PET-CT.

Br J Radiol 2019 Jan 4:20180904. Epub 2019 Jan 4.

4 Dermatology Service, Hospital Universitario, Puerta de Hierro, Majadahonda , Madrid , Spain.

Background:: Primary cutaneous lymphoma is a rare extranodal non-Hodgkin's lymphoma confined to the skin. The data on the imaging findings of primary cutaneous lymphomas are largely lacking and the current diagnosis is based on clinical and histopathological examination. With the advances in dermatological ultrasound and molecular imaging, newer perspectives in the evaluation of cutaneous lymphomas are available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20180904DOI Listing
January 2019
10 Reads

Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.

Curr Oncol 2018 Dec 1;25(6):e592-e596. Epub 2018 Dec 1.

Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC.

Primary effusion lymphoma (pel) is a rare human herpesvirus 8 (hhv8)-related large B cell lymphoma with plasmablastic, immunoblastic, or anaplastic features that often carries a poor prognosis. This lymphoma occurs mainly in patients with hiv infection, most often with Epstein-Barr virus (ebv) co-infection, and usually presents as body cavity effusions or, less commonly, as extracavitary lesions without effusion (ec-pel). Chemotherapeutic treatment options are limited and require concurrent antiretroviral therapy (art). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291272PMC
December 2018
3 Reads

Primary cutaneous B-cell lymphoma: A single-center 5-year experience.

Indian J Cancer 2018 Apr-Jun;55(2):134-137

Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India.

Background: Skin is the second most common site for extranodal non-Hodgkin's lymphoma (NHL). Most primary cutaneous NHLs are of T-cell origin (70%). Primary cutaneous B-cell lymphoma (PCBCL) is a rare entity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijc.IJC_418_17DOI Listing
January 2019
3 Reads

Adult-Onset Atopic Dermatitis.

J Allergy Clin Immunol Pract 2019 Jan;7(1):28-33

Departments of Dermatology, Preventive Medicine and Medical Social Sciences, Feinberg School of Medicine at Northwestern University, Chicago, Ill; Northwestern Medicine Multidisciplinary Eczema Center, Chicago, Ill. Electronic address:

One in 4 adults with atopic dermatitis (AD) report adult-onset disease. Adult-onset AD appears to be associated with a different disease phenotype compared with childhood-onset AD. A broad differential diagnosis must be considered in a patient presenting with an adult-onset eczematous eruption, including allergic contact dermatitis, mycosis fungoides/cutaneous T-cell lymphoma, psoriasis, scabies, and so forth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2018.09.029DOI Listing
January 2019
2 Reads

Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T-cell lymphoma.

Histopathology 2018 Dec 31. Epub 2018 Dec 31.

Department of Pathology, University of Michigan, Ann Arbor, MI.

Aims: Histopathologic overlap between lupus erythematosus and certain types of cutaneous T-cell lymphoma (CTCL) is well documented. CD123+ plasmacytoid dendritic cells (PDCs) are typically increased in lupus erythematosus, but have not been well studied in CTCL. We aimed to compare CD123 immunostaining and histopathologic features in these conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13817DOI Listing
December 2018
1 Read

CD30-positive cutaneous extranodal natural killer/T-cell lymphoma: clinicopathological features and survival outcomes.

Int J Dermatol 2018 Dec 30. Epub 2018 Dec 30.

Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Background: The prognostic value of CD30 expression in cutaneous extranodal natural killer/T-cell lymphoma is controversial.

Methods: Clinicopathological features, survival outcomes, and prognostic implications of CD30 were retrospectively analyzed in 55 patients with cutaneous extranodal natural killer/T-cell lymphoma. We classified patients into (i) primary cutaneous extranodal natural killer/T-cell lymphoma and (ii) cutaneous extranodal natural killer/T-cell lymphoma secondary to nasal disease depending on the primary tumor site. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14362DOI Listing
December 2018
1 Read

Transplantation.

Authors:
Jasmine Zain

Cancer Treat Res 2019 ;176:269-287

City of Hope National Medical Center, Duarte, CA, USA.

Mature T-cell non-Hodgkin lymphomas (T-cell NHL) are a heterogeneous group of lymphoid malignancies including NK/T-cell lymphomas. Hematopoietic cell transplantation (HCT) is an important component of the management of T-cell NHL; however, the optimal timing and type of transplant for each different subtype is an ongoing debate. For the purpose of this chapter, PTCL will be classified as (1) systemic PTCL that includes nodal as well as non-nodal histologies in PTCL (2) CTCL-or cutaneous T-cell lymphomas that arise primarily in the skin and (3) NK/T-cell lymphomas both nasal and extranasal types. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-319-99716-2_13
Publisher Site
http://dx.doi.org/10.1007/978-3-319-99716-2_13DOI Listing
January 2019
9 Reads

CD30-Positive Lymphoproliferative Disorders.

Cancer Treat Res 2019 ;176:249-268

Division of Dermatology, City of Hope National Medical Center, Duarte, CA, USA.

Primary cutaneous CD30-positive lymphoproliferative disorders (CD30+ LPD) encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions [1]. CD30+ LPD are the second most common cutaneous T-cell lymphomas (CTCL) after mycosis fungoides (MF) and represent approximately 25% of all CTCL cases [2]. Their common phenotypic hallmark is an expression of the CD30 antigen, a cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_12DOI Listing
January 2019
1 Read

Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.

Cancer Treat Res 2019 ;176:225-248

Department of Hematology/Hematopoietic Cell Transplantation, Duarte, USA.

Mycosis fungoides and Sézary syndrome are the most common subtypes of all primary cutaneous lymphomas and represent complex diseases that require a multidisciplinary assessment by dermatologists, oncologists, and pathologists. Staging and work-up are critical to guarantee an optimal treatment plan that includes skin-directed and/or systemic regimens depending on the clinical stage, tumor burden, drug-related side effect profile, and patient comorbidities. However, there is no cure and patients frequently relapse, requiring repeated treatment courses for disease control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_11DOI Listing
January 2019
11 Reads

Rare T-Cell Subtypes.

Cancer Treat Res 2019 ;176:195-224

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.

There are a number of rare T-cell lymphoma subtypes that may be encountered in clinical practice. In recent years, improved immunohistochemical techniques and molecular tumor profiling have permitted refinement of some of the diagnostic categories in this group, as well as the recognition of distinct conditions not previously well elucidated. In this chapter, we cover the diagnostic and clinical features of some of the more common of these conditions, including subcutaneous panniculitis-like T-cell lymphoma, cutaneous gamma-delta T-cell lymphoma, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma, CD4-positive small/medium T-cell lymphoproliferative disorder, and acral CD8-positive T-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_10DOI Listing
January 2019
1 Read

Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.

Cancer Treat Res 2019 ;176:127-144

Department of Laboratory Medicine, University of Washington School of Medicine, 825 Eastlake Ave. East, P.O. Box G7-800, Seattle, WA, 98109, USA.

Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature post-thymic T-cell. The contemporary World Health Organization (WHO) Classification of Haematologic Malignancies recognizes two distinct subtypes of systemic ALCL: Anaplastic Lymphoma Kinase (ALK)-negative, and ALK-positive. An additional unique subtype of ALCL is known to arise after prolonged exposure to breast implants, known as Breast Implant Associated ALCL (BIALCL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_6DOI Listing
January 2019
1 Read